| Literature DB >> 27115139 |
Swaantje Barth1, Johannes-Peter Haas2, Jenny Schlichtiger1, Johannes Molz1, Betty Bisdorff1, Hartmut Michels2, Boris Hügle2, Katja Radon1.
Abstract
OBJECTIVE: Aims of the study were to investigate health-related quality of life (HRQOL) in adult patients with former diagnosis of Juvenile Idiopathic Arthritis (JIA), to compare their HRQOL with the general population and to identify factors related to a poor outcome.Entities:
Mesh:
Year: 2016 PMID: 27115139 PMCID: PMC4846020 DOI: 10.1371/journal.pone.0153267
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Inclusion of study participants.
Socio-demographic characteristics and disease specific data of the study population.
| nmissing | n (%) | |
|---|---|---|
| 2592 (100) | ||
| Sex | 0 | |
| Female | 1617 (62.4) | |
| Age (years) | 0 | |
| 18–24 | 749 (28.9) | |
| 25–34 | 834 (32.2) | |
| 35–44 | 555 (21.4) | |
| 45–54 | 345 (13.3) | |
| 55–76 | 109 (4.2) | |
| Level of education | 14 | |
| Low | 438 (17.0) | |
| Medium | 846 (32.8) | |
| High | 1294 (50.2) | |
| Disease duration since first symptoms | 1521 | |
| Median (1./3. quartile) (range) (years) | 27 (15/40) (3–70) | |
| Age at first symptoms | 1521 | |
| Median (1./3. quartile) (range) (years) | 8 (4/11) (0–15) | |
| Currently in treatment for rheumatic disease | 4 | 1352 (52.2) |
| Currently taking drugs | 5 | 1298 (50.2) |
| Disability card holder | 6 | 934 (36.1) |
| Severe disability | 16 | 783 (30.4) |
| Psoriasis | 83 | 249 (9.9) |
Age and gender stratified comparison of the EQ5D domains between JIA patients and the German general population.
| Men (% reporting moderate or severe problems) | ||||||||
| Age in years | 18–24 | 25–34 | 35–44 | 45–54 | 55–64 | 65–74 | 75+ | Men Overall |
| German general population | 127 | 259 | 389 | 290 | 292 | 205 | 98 | 1660 |
| JIA patients | 225 | 296 | 240 | 170 | 31 | 13 | 0 | 975 |
| German general population | 0.8 | 3.1 | 6.4 | 17.2 | 20.9 | 30.2 | 41.8 | 14.9 |
| JIA patients | 7.6 | 14.5 | 13.8 | 21.2 | 29.0 | 30.8 | 0 | 18.7 |
| - | ||||||||
| German general population | 0.0 | 0.4 | 0.8 | 1.7 | 2.4 | 4.4 | 11.2 | 2.2 |
| JIA patients | 1.3 | 3.0 | 3.3 | 4.7 | 9.7 | 23.1 | 0 | 6.7 |
| - | ||||||||
| German general population | 3.2 | 1.9 | 3.9 | 10.7 | 11.0 | 17.6 | 25.5 | 8.9 |
| JIA patients | 7.1 | 13.5 | 15.0 | 21.2 | 22.6 | 30.8 | 0 | 17.6 |
| - | ||||||||
| German general population | 9.5 | 17.8 | 16.5 | 28.3 | 31.9 | 371 | 41.8 | 24.9 |
| JIA patients | 44.0 | 45.6 | 44.2 | 54.7 | 58.1 | 69.2 | 0 | 49.2 |
| - | ||||||||
| German general population | 3.9 | 3.1 | 2.3 | 4.5 | 4.1 | 3.9 | 5.1 | 3.6 |
| JIA patients | 15.6 | 17.9 | 17.9 | 27.7 | 19.4 | 15.4 | 0 | 18.3 |
| - | ||||||||
| Women (% reporting moderate or severe problems) | ||||||||
| Age in years | 18–24 | 25–34 | 35–44 | 45–54 | 55–64 | 65–74 | 75+ | Women Overall |
| German general population | 137 | 292 | 449 | 347 | 305 | 213 | 149 | 1892 |
| JIA patients | 524 | 538 | 315 | 175 | 55 | 10 | 0 | 1617 |
| German general population | 4.4 | 4.8 | 4.2 | 11.5 | 22.3 | 37.6 | 61.1 | 16.8 |
| JIA patients | 15.5 | 22.1 | 27.0 | 39.4 | 43.6 | 50.0 | 0 | 30.8 |
| - | ||||||||
| German general population | 0.7 | 0.3 | 1.3 | 2.0 | 2.0 | 7.0 | 18.8 | 3.4 |
| JIA patients | 3.2 | 6.3 | 11.1 | 18.9 | 14.6 | 40.0 | 0 | 14.2 |
| - | ||||||||
| German general population | 4.4 | 4.5 | 3.8 | 5.5 | 15.4 | 19.7 | 38.9 | 10.7 |
| JIA patients | 16.6 | 22.1 | 31.1 | 37.7 | 41.8 | 60.0 | 0 | 32.4 |
| - | ||||||||
| German general population | 16.1 | 17.8 | 20.9 | 27.1 | 37.7 | 47.4 | 59.7 | 30.0 |
| JIA patients | 57.3 | 67.1 | 65.1 | 66.3 | 72.7 | 80.0 | 0 | 62.8 |
| - | ||||||||
| German general population | 5.1 | 4.1 | 4.2 | 5.2 | 4.6 | 5.6 | 6.7 | 4.9 |
| JIA patients | 25.8 | 29.7 | 31.4 | 38.3 | 41.8 | 80.0 | 0 | 36.7 |
| - | ||||||||
Δ: Difference between German general population and JIA patients.
a German data of König et al 2009;
b Data for the JIA patients directly age and sex standardized to the general population.
Overall comparison of problems in EQ5D domains between JIA patients and the German general population.
| Overall | |
|---|---|
| % (95%-CI) | |
| 3552 | |
| 2592 | |
| 15.9 (14.8;17.2) | |
| 25.2 (23.7;26.6) | |
| 9.2 | |
| 2.8 (2.3;3.4) | |
| 10.7 (9.7;11.8) | |
| 7.9 | |
| 9.9 (8.9;10.9) | |
| 25.5 (24.1;27.0) | |
| 15.7 | |
| 27.6 (26.2;29.1) | |
| 56.4 (54.8;58.1) | |
| 28.8 | |
| 4.3 (3.6;5.0) | |
| 28.1 (26.6;29.6) | |
| 23.8 |
95%-CI: 95% Confidence Interval. Δ: Difference between German general population and JIA patients.
a German data of König et al 2009;
b Data for the JIA patients directly age and sex standardized to the general population.
Fig 2Health-related quality of life in JIA patients and the general German population.
Age and gender standardized prevalence of problems in the five EQ5D dimensions with 95% confidence intervals.
Associations between general and disease specific factors and HRQOL in JIA patients. Results of bivariate analyses and logistic regression models with EQ5DIndex as Outcome.
| Low HRQOL (low EQ5DIndex) | ||||
|---|---|---|---|---|
| OR (95% CI) | ||||
| Complete cases n = 2456 | % (n) | pChi2 | Crude OR | Adjusted OR |
| Sex | ||||
| Male | 7.63 (70) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| Female | 14.55 (224) | |||
| Age | ||||
| 18–24 years | 7.31 (52) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| 25–34 years | 11.82 (94) | |||
| 35–44 years | 11.13 (58) | 1.43 (0.94;2.18) | ||
| 45–54 years | 20.18 (66) | |||
| 55–76 years | 23.53 (24) | |||
| Level of education | ||||
| High | 8.02 (100) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| Medium | 14.11 (113) | |||
| Low | 19.85 (81) | |||
| Currently in treatment for rheumatism | ||||
| No | 3.66 (43) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| Yes | 19.58 (251) | |||
| Currently taking drugs | ||||
| No | 3.60 (44) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| Yes | 20.28 (250) | |||
| Disability card holder | ||||
| No | 4.80 (75) | p<0.001 | 1.00 (Ref.) | 1.00 (Ref.) |
| Yes | 24.55 (219) | |||
| Severe disability | ||||
| No (DoB <50) | 8.09 (11) | p<0.001 | n. r. | n. r. |
| Yes (DoB ≥50) | 27.61 (206) | |||
| No disability | 4.80 (75) | |||
| Psoriasis | ||||
| No | 11.31 (250) | p = 0.002 | 1.00 (Ref.) | 1.00 (Ref.) |
| Yes | 17.96 (44) | 1.38 (0.93;2.05) | ||
| Disease duration since first symptoms | ||||
| 0–5 years | 18.75 (3) | p<0.001 | n. r. | n. r. |
| 6–10 years | 7.14 (6) | |||
| 11–20 years | 8.70 (26) | |||
| 21–40 years | 12.21 (48) | |||
| 41-max years | 24.20 (53) | |||
| Age at first symptoms | ||||
| 0–2 years | 17.50 (28) | p = 0.041 | n. r. | n. r. |
| 3–5 years | 15.46 (32) | |||
| 6–8 years | 13.86 (28) | |||
| 9–10 years | 7.25 (10) | |||
| 11–12 years | 9.26 (15) | |||
| 13–15 years | 16.20 (23) | |||
OR: Odds Ratio, 95% CI: 95% confidence interval, Ref: reference, HRQOL: health-related quality of life, n.r.: not reported. Complete case analyses n = 2456. Low EQ VAS was defined by 1st decile of EQ VAS values (<50). Low EQ5DIndex was defined by 1st decile of EQ5DIndex values (≤0.622). The five dimensions of EQ5D were dichotomized to presence (moderate and severe problems) and absence of problems, having problems was used as outcome.
a mutual adjustment for all other variables listed in the table.
bVariables excluded from multivariate analyses due to multi-collinearity.